| 卜珊珊,丁丹红,王修身.同步放化疗前食管鳞癌患者血清Galectin-3的表达及预后价值[J].中国肿瘤,2018,27(5):376-381. |
| 同步放化疗前食管鳞癌患者血清Galectin-3的表达及预后价值 |
| Serum Galectin-3 Level in Esophageal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiotherapy and Its Prognostic Value |
| 投稿时间：2018-01-21 |
| DOI：10.11735/j.issn.1004-0242.2018.05.A011 |
|
 |
| 中文关键词: 食管鳞癌(ESCC) 血清 半乳糖凝集素-3(Galectin-3) 同步放化疗 预后 |
| 英文关键词:esophageal squamous cell carcinoma(ESCC) serum galectin-3 concurrent chemoradiotherapy prognosis |
| 基金项目: |
|
| 摘要点击次数: 1688 |
| 全文下载次数: 426 |
| 中文摘要: |
| 摘 要：［目的］ 检测健康人及食管鳞癌（ESCC）患者治疗前血清Galectin-3表达水平，分析Galectin-3表达水平与ESCC患者临床特征及同步放化疗后预后之间的关系。［方法］ 采用酶联免疫吸附试验检测ESCC患者及健康人血清Galectin-3的表达水平，分析二者的表达差异；分析ESCC患者血清中Galectin-3表达水平与临床分期、肿瘤部位、肿瘤长度、有无淋巴结转移和远处转移的关系；采用Kaplan-Meier法探讨ESCC患者血清Galectin-3表达水平对同步放化疗治疗后总生存率及无进展生存率的影响。［结果］ ESCC患者组血清Galectin-3的表达水平明显高于健康人对照组，分别为（9.703±1.310）ng/ml和（7.858±1.017）ng/ml，差异有统计学意义（P=0.000）。根据ROC曲线，确定Galectin-3对ESCC诊断的界值为9.0ng/ml，Galectin-3诊断ESCC的敏感性、特异性和准确性分别为69.0%、87.2%和86.0%。血清Galectin-3表达水平受肿瘤长度的影响（P=0.003）。血清Galectin-3表达水平≥9.0ng/ml和<9.0ng/ml的1年无进展生存率分别为47.4％和75.0％(P=0.037)。［结论］ ESCC患者血清中Galectin-3的表达水平受病变长度的影响。除临床分期外，ESCC患者治疗前血清Galectin-3的表达水平有可能作为一个独立的预后指标。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate serum galectin-3 levels in esophageal squamous cell carcinoma(ESCC) patients treated with concurrent chemoradiotherapy and its prognostic value. ［Methods］ The serum levels of galectin-3 in 32 ESCC patients(ESCC group) and 39 healthy subjects(control group) were determined by ELISA. The association of the galectin-3 level with the clinical stage，tumor site，tumor size，lymph node metastasis and distant metastasis in ESCC patients was analyzed. The correlation of serum galectin-3 level with the overall survival（OS） and progression-free survival（PFS）of ESCC patients after concurrent radiochemotherapy was also analyzed. ［Results］ Serum galectin-3 expression level in ESCC patients was significantly higher than that in healthy controls［(9.703±1.310)ng/ml vs (7.858±1.017)ng/ml，P=0.000］. According to the ROC curve 9.0ng/ml was taken as cut-off value，the sensitivity，specificity and accuracy of serum galectin-3 for diagnosis of ESCC were 69.0%，87.2% and 86%，respectively. Serum galectin-3 level was correlated with the size of tumor（P=0.003）. The one-year PFS in patients with high serum galectin-3(≥9.0ng/ml) was significantly lower than that with low serum galectin-3(<9.0ng/ml)( 47.4％ vs 75.0％，P=0.037). ［Conclusion］ Serum galectin-3 levels in the patients with ESCC were associated by the tumor size. And serum galectin-3 level before treatment might be used as a prognostic indicator for ESCC patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |